271 related articles for article (PubMed ID: 32985015)
1. Efficacy of BRAF-Inhibitor Therapy in BRAF
Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
Li Q
J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
[TBL] [Abstract][Full Text] [Related]
3. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
[TBL] [Abstract][Full Text] [Related]
4. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
7. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
8. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
10. [Status of Langerhans cell histiocytosis in children and adults].
Kudo K
Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
[TBL] [Abstract][Full Text] [Related]
11. A circulating subset of BRAF
Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
[TBL] [Abstract][Full Text] [Related]
12. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
[TBL] [Abstract][Full Text] [Related]
14. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
15. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
[TBL] [Abstract][Full Text] [Related]
16. Apparent Lack of
Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
Front Immunol; 2019; 10():3045. PubMed ID: 31998317
[TBL] [Abstract][Full Text] [Related]
17. ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients.
Nellan A; Bodlak A; Mirsky DM; Mulcahy Levy J; Garrington TP; Foreman NK; Gilani A; Hayashi M
J Neuropathol Exp Neurol; 2020 Dec; 79(12):1313-1319. PubMed ID: 32930721
[TBL] [Abstract][Full Text] [Related]
18. Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.
Arceci RJ
Am Soc Clin Oncol Educ Book; 2014; ():e441-5. PubMed ID: 24857137
[TBL] [Abstract][Full Text] [Related]
19.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
20. High Prevalence of
Liu X; Zhang Y; Zhou CX
Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
